Behavioral and pathological outcomes in MOG 35–55 experimental autoimmune encephalomyelitis
Authors:
- P.A. CalabresiPCP.A. Calabresi
- 1 August 2008
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 199 (1-2) , 83-93
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepineAnnals of Neurology, 2007
- Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitisJournal of Comparative Neurology, 2007
- Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAEBrain, 2006
- Multiple Sclerosis — The Plaque and Its PathogenesisNew England Journal of Medicine, 2006
- The spectrum of multiple sclerosis: new lessons from pathologyCurrent Opinion in Neurology, 2005
- Time-course expression of CNS inflammatory, neurodegenerative tissue repair markers and metallothioneins during experimental autoimmune encephalomyelitisNeuroscience, 2005
- Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosisBrain Research, 2003
- A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesionsNature Genetics, 2002
- Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell CulturesJournal of Neuroscience, 2002
- Two models of multiple sclerosis: Experimental allergic encephalomyelitis (EAE) and theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparisonMicroscopy Research and Technique, 1995